A Case of Sirolimus-Induced Interstitial Lung Disease After Liver Transplantation

Narendra S Choudhary; Sanjiv Saigal; Amey Sonavane; Ashish K Prakash; Arvind Pandey; Neeraj Saraf; Arvinder S Soin

doi:10.1016/j.jceh.2018.09.005

A Case of Sirolimus-Induced Interstitial Lung Disease After Liver Transplantation

J Clin Exp Hepatol. 2019 Jul-Aug;9(4):539-540. doi: 10.1016/j.jceh.2018.09.005. Epub 2018 Oct 5.

Authors

Narendra S Choudhary¹, Sanjiv Saigal¹, Amey Sonavane¹, Ashish K Prakash², Arvind Pandey³, Neeraj Saraf¹, Arvinder S Soin¹

Affiliations

¹ Medanta Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurgaon, Delhi (NCR), India.
² Department of Respiratory Medicine and Sleep Medicine, Medanta The Medicity, Gurgaon, Delhi (NCR), India.
³ Department of Radiodiagnosis, Medanta The Medicity, Gurgaon, Delhi (NCR), India.

Abstract

Mammalian target of rapamycin inhibitors (mTORis) are immunosuppression agents that are commonly used in solid organ transplantation. Available mTORis include sirolimus and everolimus. Interstitial lung disease (ILD) is an uncommon side effect of mTORis in liver transplantation. A high index of suspicion is needed, and timely intervention can reverse the disease. We present a case of sirolimus-induced ILD that improved after discontinuation of sirolimus.

Keywords: HCC, hepatocellular carcinoma; ILD, Interstitial lung disease; dyspnea; interstitial lung disease; liver transplantation; mTORi, Mammalian target of rapamycin inhibitor; pulmonary; sirolimus.